跳至主要内容
临床试验/NCT06089421
NCT06089421招募中不适用

A Prospective, Randomized Trial to Compare Telegenetics to Counseling Via a Novel Genetic Information Assistant in High-risk Cancer Patients.

University of Virginia2 个研究点 分布在 1 个国家目标入组 96 人开始时间: 2025年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
96
试验地点
2
主要终点
To assess feasibility of using a chatbot (GIA) for pre-test genetic counseling compared to standard of care GC

研究概览

简要总结

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is:

• Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing?

Participants will:

  • have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot
  • answer questions about their cancer genetic knowledge and how they are doing
  • provide a saliva sample for genetic testing to test for cancer gene mutations
  • have their genetic testing results provided to them.
  • have the option to share their genetic testing results with family members

Researchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.

详细描述

High risk patients will be randomized to standard of care telegenetics with a UVA Genetic Counselor (GC) for pre-test counseling or to the novel interventional arm of pre-test counseling via Genetic Information Assistant (GIA). Participants in the study will receive their link for a telegenetics appointment or GIA link based on randomization and patients will complete pre-test genetic counseling via their assigned treatment arm. Participants will not be masked to their trial arm assignment. In the telegenetics arm, patients will be offered a video visit scheduled through Epic zoom or a phone visit in our cancer genetics clinic per standard of care. Patients randomized to the GIA arm will receive a personalized link based on their family history. At the completion of counseling, participants will be offered genetic testing. If they agree, they will be mailed a saliva kit via Invitae Genetics for panel based genetic testing via The Invitae Common Hereditary Cancers panel to analyze 47 genes associated with cancers of the breast, ovary, uterus, and gastrointestinal system, which includes the stomach, colon, rectum, small bowel, and pancreas.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Screening
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •At high risk for having a genetic pathogenic variant as assessed by a GC or physician according to the NCCN guidelines
  • •Provision of signed and dated informed consent form.
  • •Stated willingness to comply with all study procedures and availability for the duration of the study.
  • •Male or female, aged 18 and over.
  • •Subjects must have a smartphone with access to cellular and/or internet service or a computer with internet service.
  • •Subjects must have technological competency/proficiency to use their Smartphone and/or computer in conjunction with the communication aid GIA.

排除标准

  • •Cannot communicate in English or Spanish.
  • •Subjects must not have completed panel-based cancer genetic testing in the past.

研究组 & 干预措施

Standard of care telegenetics with a UVA genetic counselor (GC) for pre-test counseling

Active Comparator

Pre-genetic test counselling with a genetic counselor from the University of Virginia

干预措施: Telegenetics with UVA genetic counselor (Other)

Novel interventional arm of pre-test counseling via GIA

Experimental

Pre-genetic test counselling through novel chat bot Genetic Information Assistant (GIA)

干预措施: Genetic Information Assistant (Other)

结局指标

主要结局

To assess feasibility of using a chatbot (GIA) for pre-test genetic counseling compared to standard of care GC

时间窗: 3 months

dichotomous measurement of whether the randomized participant completes genetic testing within three months.

次要结局

  • To assess differences of SURE scale(6 months)
  • To assess differences of Decisional Conflict scale(6 months)
  • To assess differences of Comprehensive Score of Financial Toxicity scale(6 months)
  • To assess differences of Multi-dimensional Impact of Cancer Risk Assessment (MICRA) scale(6 months)
  • To test cancer knowledge following the pre-test genetic counseling with GIA versus GC(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kari Ring, MD

Assistant Professor

University of Virginia

研究点 (2)

Loading locations...

相似试验

已完成
不适用
Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast CancerBreast Cancer
NCT04354675Case Comprehensive Cancer Center35
进行中(未招募)
2 期
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
NCT01334021M.D. Anderson Cancer Center1,100
Unknown
不适用
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient CareArthritisMental DisordersCardiovascular DiseasesChronic PainPainDiabetes Mellitus, Type 2
NCT02487888Proove Bioscience, Inc.100,000
已完成
不适用
Streamlined Genetic Testing in Prostate CancerProstate Cancer
NCT04359758Georgetown University112
已完成
不适用
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH TrialRefractory Mantle Cell LymphomaRecurrent Mantle Cell Lymphoma
NCT04872413M.D. Anderson Cancer Center1